Brokerages predict that INmune Bio Inc (NASDAQ:INMB) will report earnings of ($0.18) per share for the current quarter, according to Zacks. Zero analysts have made estimates for INmune Bio’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.20). INmune Bio posted earnings of ($0.04) per share during the same quarter last year, which would suggest a negative year over year growth rate of 350%. The firm is expected to announce its next earnings results on Monday, August 10th.

According to Zacks, analysts expect that INmune Bio will report full-year earnings of ($0.68) per share for the current fiscal year, with EPS estimates ranging from ($0.71) to ($0.64). For the next fiscal year, analysts expect that the business will report earnings of ($0.86) per share, with EPS estimates ranging from ($1.22) to ($0.61). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for INmune Bio.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.02.

INMB has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (up from $7.00) on shares of INmune Bio in a research note on Friday, May 15th. Maxim Group initiated coverage on INmune Bio in a research note on Saturday, May 16th. They issued a “buy” rating and a $13.00 target price for the company.

INmune Bio stock traded down $0.06 during trading on Monday, hitting $5.00. The company’s stock had a trading volume of 69,300 shares, compared to its average volume of 38,928. The stock has a market capitalization of $54.57 million, a price-to-earnings ratio of -7.11 and a beta of 2.41. The stock’s fifty day moving average is $5.62 and its 200 day moving average is $4.86. INmune Bio has a 1-year low of $2.20 and a 1-year high of $10.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.25 and a current ratio of 6.25.

A number of institutional investors have recently added to or reduced their stakes in INMB. Financial Advocates Investment Management increased its stake in INmune Bio by 12.8% in the first quarter. Financial Advocates Investment Management now owns 253,461 shares of the company’s stock valued at $844,000 after purchasing an additional 28,794 shares during the last quarter. BlackRock Inc. increased its stake in INmune Bio by 140.4% during the first quarter. BlackRock Inc. now owns 15,752 shares of the company’s stock worth $52,000 after acquiring an additional 9,200 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in INmune Bio by 21.7% during the first quarter. Deutsche Bank AG now owns 56,048 shares of the company’s stock worth $187,000 after acquiring an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 3.17% of the company’s stock.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

See Also: What are Institutional Investors?

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.